Vascular events with placebo
| COX 2 inhibitor | No of trials (Placebo) | Events/person years | |
|---|---|---|---|
| Allocated COX 2 Inhibitor | Allocated NSAID | ||
| Refecoxib | 37 | 98/6,638 | 72/6,415 |
| Celecoxib | 41 | 84/8,976 | 29/4,953 |
| Etoricoxib | 17 | 7/753 | 2/414 |
| Lumiracoxib | 12 | 14/1,375 | 6/584 |
| Valdecoxib | 14 | 13/748 | 3/273 |
| Subtotal | 121 | 216/18,490 (1.2%/year) | 112/12,639 (0.9%/year) |
| Values | Heterogeneity among five drugs:: χ2=10.2, df=1, |
||
| Rate ratio | 1.42, 95% confidence interval 1.13 to 1.78, |
||
